SCHEMBL366474

SCHEMBL366474

CS(=O)(=O)c1ccc(C(N)=O)c([N+](=O)[O-])c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.51
ALDH3A1 P30838 3/20 0.49
MAPT P10636 4/20 0.47
LMNA P02545 3/20 0.47
GAA P10253 1/20 0.47
CA12 O43570 2/20 0.46
CA1 P00915 2/20 0.46
CA2 P00918 2/20 0.46
CA9 Q16790 2/20 0.46
CYP3A4 P08684 1/20 0.44
BLM P54132 1/20 0.44
PMP22 Q01453 1/20 0.44
PKM P14618 2/20 0.44
KMT2A Q03164 4/20 0.44
MEN1 O00255 3/20 0.43
RAB9A P51151 2/20 0.43
NPC1 O15118 1/20 0.43
MITF O75030 1/20 0.43
MAPK1 P28482 1/20 0.43
HTT P42858 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrogen Peroxide SCHEMBL28991385 0.85 ALDH1A1 (0.56) ALDH1A1ALDH3A1MAPTLMNAGAA
SCHEMBL1202449 0.85 ALDH1A1 (0.56) ALDH1A1ALDH3A1MAPTLMNAGAA
SCHEMBL18287474 0.85 ALDH3A1 (0.53) ALDH1A1ALDH3A1MAPTLMNAGAA
SCHEMBL28991384 0.84 ALDH1A1 (0.49) ALDH1A1ALDH3A1MAPTLMNAGAA
SCHEMBL9083437 0.84 ALDH3A1 (0.47) ALDH1A1ALDH3A1MAPTLMNAGAA
SCHEMBL29035610 0.84 ALDH1A1 (0.52) ALDH1A1ALDH3A1MAPTLMNAGAA
SCHEMBL2084156 0.84 ALDH1A1 (0.51) ALDH1A1ALDH3A1MAPTLMNAGAA
SCHEMBL30595897 0.84 ALDH1A1 (0.51) ALDH1A1ALDH3A1MAPTLMNAGAA
Lithium Ion SCHEMBL29035600 0.84 ALDH1A1 (0.51) ALDH1A1ALDH3A1MAPTLMNAGAA
SCHEMBL28435633 0.84 ALDH1A1 (0.55) ALDH1A1ALDH3A1MAPTLMNAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230054411-A1 7-, 8-, and 10-SUBSTITUTED AMINO TRIAZOLO QUINAZOLINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE MERCK SHARP & DOHME CORP. (US) 2023-02-23 US disclosed
US-10357577-B2 Bacterial nitroreductase enzymes and methods relating thereto AUCKLAND UNISERVICES LIMITED (NZ) 2019-07-23 US disclosed
US-20130295011-A1 BACTERIAL NITROREDUCTASE ENZYMES AND METHODS RELATING THERETO VICTORIA LINK LIMITED (NZ) 2013-11-07 US disclosed
EP-2593796-A2 BACTERIAL NITROREDUCTASE ENZYMES AND METHODS RELATING THERETO Auckland Uniservices Limited (NZ) 2013-05-22 EP disclosed
WO-2012008860-A2 BACTERIAL NITROREDUCTASE ENZYMES AND METHODS RELATING THERETO AUCKLAND UNISERVICES LIMITED (NZ) 2012-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230054411-A1 7-, 8-, and 10-SUBSTITUTED AMINO TRIAZOLO QUINAZOLINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE ADORA2A, ADORA2B, ADORA3 ALDH1A1 1156/4885ALDH3A1 1158/4885MAPT 4540/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.